A Study to Examine APL-130277 in Patients With Parkinson's Disease
NCT02228590
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Parkinson's Disease
Interventions
DRUG:
APL-130277
Sponsor
Sumitomo Pharma America, Inc.